News

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

 Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma...

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of...

Providence Announces Positive Top-Line Data from Phase 2 Primary Immunization Trial of its mRNA Vaccine Candidate PTX-COVID19-B in Adults

PTX-COVID19-B was well tolerated with no safety signalsNon-inferior neutralizing antibody titer levels versus comparator vaccine, Comirnaty®Providence will initiate a Phase...

Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

SEATTLE, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune...

Galecto’s Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Simply Better Brands Corp, Growing 359% vs Year Ago Preliminarily Sales Results Year to Date, Announces Its Trubar Brand’s Accelerated Expansion of Its Portfolio and Distribution

Women-founded, Women-led Nutrition Brand Expands Dessert-inspired, Plant-Based brand in flavor innovation, category expansion and retail footprint TRUBAR 2021 vs 2022...

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological EndpointsWALTHAM, Mass., Oct. 19, 2022...

error: Content is protected !!